Citadel Advisors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-35,816
| Closed | -$537K | – | 8226 |
|
|
2016
Q2 | $537K | Buy |
+35,816
| New | +$460K | ﹤0.01% | 4390 |
|
|
2016
Q1 | – | Sell |
-23,799
| Closed | -$379K | – | 8948 |
|
|
2015
Q4 | $379K | Buy |
+23,799
| New | +$375K | ﹤0.01% | 4865 |
|
|
2015
Q3 | – | Sell |
-77,385
| Closed | -$1.88M | – | 9521 |
|
|
2015
Q2 | $1.88M | Sell |
77,385
-95,106
| -55% | -$2.28M | ﹤0.01% | 3132 |
|
|
2015
Q1 | $4.01M | Buy |
172,491
+55,614
| +48% | +$1.47M | ﹤0.01% | 2263 |
|
|
2014
Q4 | $2.94M | Buy |
+116,877
| New | +$3.43M | ﹤0.01% | 2499 |
|
|
2014
Q3 | – | Sell |
-21,752
| Closed | -$562K | – | 8669 |
|
|
2014
Q2 | $562K | Sell |
21,752
-520,506
| -96% | -$11.6M | ﹤0.01% | 4245 |
|
|
2014
Q1 | $12.7M | Buy |
+542,258
| New | +$11.9M | 0.01% | 1118 |
|
|
2013
Q4 | – | Sell |
-21,697
| Closed | -$443K | – | 7327 |
|
|
2013
Q3 | $443K | Buy |
21,697
+2,778
| +15% | +$61.8K | ﹤0.01% | 3935 |
|
|
2013
Q2 | $397K | Buy |
+18,919
| New | +$338K | ﹤0.01% | 4065 |
|
Citadel Advisors's SGNT Position: Q3 2016 in Review
Citadel Advisors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 35,816 shares — an estimated $537K sold.
Citadel Advisors first reported a position in SGNT in Q2 2013 and held it in 9 quarters. The position peaked at $12.7M in Q1 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Citadel Advisors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Citadel Advisors sold 35,816 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $537K.
- Citadel Advisors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 9 quarters.
- Citadel Advisors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $12.7M in Q1 2014.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Citadel Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.